

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee (pedsODAC) Meeting*
June 16, 2023

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Takyiah Stevenson, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

David E. Mitchell

(Consumer Representative)
President, Patients for Affordable Drugs
Bethesda, Maryland

Alberto S. Pappo, MD

(Chairperson, pedsODAC)
Member, St. Jude Faculty
Director, Solid Tumor Division
Co-Leader, Developmental Biology & Solid
Tumor Program
Alvin Mauer Endowed Chair
St. Jude Children's Research Hospital
Memphis, Tennessee

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)
Senior Vice President
Head of Oncology Development
Global Drug Development
Bristol-Myers Squibb
Lawrenceville, New Jersey

TEMPORARY MEMBERS (Voting)

Frank M. Balis, MD

Professor of Pediatrics
Division of Oncology
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Steven G. DuBois, MD

Director, Experimental Therapeutics
Dana-Farber/Boston Children's Hospital
Associate Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Julia Glade Bender, MD

Vice Chair for Clinical Research
Member, Memorial Hospital
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, New York

E. Anders Kolb, MD

President and Chief Executive Officer
The Leukemia and Lymphoma Society
Rye Brook, New York

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee (pedsODAC) Meeting*
June 16, 2023

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Theodore W. Laetsch, MD

Associate Professor of Pediatrics
Division of Pediatric Oncology
Children's Hospital of Philadelphia
University of Pennsylvania
Philadelphia, Pennsylvania

Donna Ludwinski, BSChE

(Patient Representative)
New York, New York

Holly Meany, MD

Associate Professor of Pediatrics
Division of Oncology
Children's National Hospital
Washington, District of Columbia

Rajen Mody, MD, MS

Ruth Heyn Endowed Chair in Pediatric Oncology
Professor and Director, Division of Pediatric
Hematology/Oncology/Bone Marrow Transplant
Michigan Medicine
Ann Arbor, Michigan

Donald (Will) Parsons, MD, PhD

Deputy Director, Texas Children's Cancer and
Hematology Center
Professor, Department of Pediatrics
Baylor College of Medicine
Houston, Texas

Malcolm A. Smith, MD, PhD

Cancer Therapy Evaluation Program
National Cancer Institute
Bethesda, Maryland

Yoram Unguru, MD, MS, MA, HEC-C

Attending Physician
Division of Pediatric Hematology/Oncology
The Herman and Walter Samuelson Children's
Hospital at Sinai
Chairman, Sinai Hospital Ethics Committee
Core Faculty, Johns Hopkins Berman Institute of
Bioethics
Associate Professor, Johns Hopkins University
School of Medicine
Baltimore, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee (pedsODAC) Meeting*
June 16, 2023

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Office of the Commissioner (OC)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Martha Donoghue, MD

Associate Director for Pediatric Oncology
OCE, OC, OOD, OND, CDER, FDA

Elizabeth S. Duke, MD

Medical Officer
Division of Oncology 2 (DO2)
OOD, OND, CDER, FDA

Ruby Leong, PharmD, LCDR, USPHS

Clinical Pharmacology Team Leader
Division of Cancer Pharmacology I
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS)
CDER, FDA

Stacy S. Shord, PharmD, BCOP, FCCP

Deputy Division Director
Division of Cancer Pharmacology II
OCP, OTS, CDER, FDA

Xiaofei Wang, PhD

Clinical Pharmacology Reviewer
Division of Clinical Evaluation General Medicine
Office of Clinical Evaluation (OCE)
Office of Therapeutic Products (OTP)
Center for Biologics Evaluation and
Research (CBER), FDA

Kristin Wessel, MD

Medical Officer
DO2, OOD, OND, CDER, FDA